Women's Health Clinical Trials in the UK (2026): Endometriosis, Breast Cancer, Ovarian Cancer
Women's health conditions have historically been under-researched, but clinical trials are beginning to close this gap. From endometriosis to breast and ovarian cancer, UK trials are exploring new treatments specifically designed for conditions that predominantly affect women. This guide covers the latest research and how to get involved.
Endometriosis: A Research Priority
Endometriosis affects 1 in 10 women in the UK, yet diagnosis still takes an average of 8 years and treatment options remain limited. Clinical trials are starting to address this neglect. New trials are testing GnRH antagonists that manage pain without the menopausal side effects of older hormonal treatments, anti-inflammatory approaches, and improved surgical techniques. Diagnostic trials are testing blood biomarkers and imaging techniques that could dramatically shorten the time to diagnosis.
Breast Cancer: Personalised Treatment Trials
The UK runs one of the world's most active breast cancer trial programmes. Current trials focus on personalised treatment — using genetic testing of tumours to select the most effective therapy for each patient. For women with BRCA mutations, PARP inhibitor trials offer targeted treatment options. Other trials test de-escalation strategies (less treatment for early-stage cancers with excellent prognosis), new antibody-drug conjugates, and immunotherapy combinations for triple-negative breast cancer.
Ovarian Cancer: Early Detection and Targeted Treatment
Ovarian cancer is often diagnosed at a late stage because early symptoms are vague and no reliable screening test exists. UK trials are addressing both challenges. Screening trials test blood biomarkers and imaging for early detection. Treatment trials focus on PARP inhibitors (particularly effective in BRCA-mutation carriers), antibody-drug conjugates, and maintenance therapies that extend remission after initial treatment.
Closing the Gender Data Gap in Research
Historically, clinical trials disproportionately studied men, leading to gaps in understanding how treatments work in women. Modern UK trials are required to include diverse populations and analyse results by sex. Many women's health trials now specifically investigate sex-based differences in treatment response, drug metabolism, and disease progression, ensuring that evidence-based medicine truly applies to all patients.